Idefirix Market Report 2026

Idefirix Market Overview

• The Idefirix market growth in the historic period has been driven by organ shortage for kidney transplantation, high prevalence of donor specific antibodies • Market expansion is supported by rising demand for kidney transplants, expansion of transplant waiting lists • Growth Driver: Rising Prevalence and Incidence of Kidney Diseases Fueling Idefirix Market Growth • Market Trend: Growing Innovation In Desensitization Treatments For Highly Sensitized Kidney Transplant Patients • Europe was the largest region and fastest growing region.

What Is Covered Under Idefirix Market?

Idefirix (imlifidase) is an enzyme-based medication designed to reduce donor-specific antibodies in highly sensitized kidney transplant patients, enabling successful organ transplantation. It is used to desensitize patients awaiting kidney transplants by cleaving IgG antibodies, increasing compatibility with available donors. The main patient demographics of Idefirix are pediatric patients and adult patients. Pediatric patients are children or adolescents who require medical care tailored to their developmental and physiological needs. It is used in applications such as kidney transplantation and desensitization protocols. The end users of Idefirix are hospitals, specialized clinics, and home healthcare. It is distributed through distribution channels such as direct sales and pharmacies.

What Is The Idefirix Market Growth Forecast?

The growth in the forecast period can be attributed to rising demand for kidney transplants, expansion of transplant waiting lists, increasing adoption of precision immunology, supportive regulatory pathways, growth in specialized transplant clinics. Major trends in the forecast period include rising use of desensitization therapies in transplantation, growing focus on highly sensitized patients, expansion of enzyme based immunomodulation, increasing kidney transplant volumes, improved access to advanced transplant care.

What Is The Driver Of The Idefirix Market?

The increasing prevalence and incidence of kidney diseases is expected to propel the growth of the idefirix market going forward. Kidney diseases are conditions that damage the kidneys' function or structure, hindering their ability to filter waste and maintain fluid balance in the body. The increasing prevalence and incidence of kidney diseases can be attributed to factors such as an aging population, rising rates of diabetes and hypertension, lifestyle choices, and genetic predispositions. Idefirix, a groundbreaking immunoglobulin G (IgG)-degrading enzyme therapy, helps kidney disease patients by enabling highly sensitized individuals to undergo life-saving kidney transplants by effectively reducing donor-specific antibodies that would otherwise cause transplant rejection. For instance, in June 2023, according to a report published by the kidney research, a UK-based research organization, the incidence of acute kidney injury is projected to increase from an estimated 615,000 cases in 2022 to 637,000 by 2033. Therefore, increasing prevalence and incidence of kidney diseases is driving the growth of the idefirix industry.

Key Players In The Global Idefirix Market

Major companies operating in the idefirix market are Hansa Biopharma AB

Global Idefirix Market Trends and Insights

The key trend in the idefirix market is focusing on developing innovative solutions, such as desensitization treatment, to desensitize highly sensitized kidney transplant patients. Desensitization treatment is a medical procedure that removes or reduces harmful antibodies, enabling transplant patients to receive organs from incompatible donors. For instance, in July 2023, Hansa Biopharma, a Sweden-based biopharmaceutical company, announced that the Australian Therapeutic Goods Administration (TGA), an Australia-based regulatory authority, approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients. This approval enables these patients to receive kidney transplants from both living and deceased donors. The treatment works by reducing or removing harmful anti-donor antibodies, which can otherwise prevent transplantation. Based on positive results from Hansa Biopharma's phase 2 studies, this approval marks a significant step in improving kidney transplant options for highly sensitized patients in Australia.

What Are Latest Mergers And Acquisitions In The Idefirix Market?

In January 2024, Hansa Biopharma AB, a Sweden-based biopharmaceutical company, entered into a partnership with NewBridge Pharmaceuticals. With this partnership, Hansa aims to expand patient access to its desensitization therapy in kidney transplantation by leveraging NewBridge’s regional commercial capabilities and regulatory expertise. NewBridge Pharmaceuticals is a UAE-based pharmaceutical company that offers Idefirix.

What Defines the Idefirix Market?

The idefirix market consists of sales of lyophilized powders and injectable solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Idefirix Market Report 2026?

The idefirix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the idefirix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.